Immunoreceptor engineering and synthetic cytokine signaling for therapeutics

J Scheller, E Engelowski, JM Moll, DM Floss - Trends in immunology, 2019 - cell.com
J Scheller, E Engelowski, JM Moll, DM Floss
Trends in immunology, 2019cell.com
Cytokines control immune-related events and are critically involved in a plethora of
physiological and pathophysiological processes including autoimmunity and cancer
development. Accordingly, modulation of natural cytokine signaling by antibodies and small
molecules has improved therapeutic regimens. Synthetic biology sets out to optimize
immunotherapeutics, with chimeric antigen receptor (CAR) T cell immmunotherapy being
the first example to combine synthetic biology with genetic engineering during therapy …
Cytokines control immune-related events and are critically involved in a plethora of physiological and pathophysiological processes including autoimmunity and cancer development. Accordingly, modulation of natural cytokine signaling by antibodies and small molecules has improved therapeutic regimens. Synthetic biology sets out to optimize immunotherapeutics, with chimeric antigen receptor (CAR) T cell immmunotherapy being the first example to combine synthetic biology with genetic engineering during therapy. Hence, synthetic cytokines and cytokine receptors, as well as constitutively active cytokine receptor variants, are emerging as tools to improve or modulate immunotherapeutic strategies. This review focuses on recent developments in the growing field of synthetic cytokine signaling, providing an outlook for developing applications that involve physiological targets of immunotherapy.
cell.com